先声药业(02096.HK)SIM0505获发药物临床试验批准通知书

阿斯达克财经
Jan 06, 2025

先声药业(02096.HK) 公布,于1月2日,集团自主研发的抗肿瘤候选药物CDH6抗体偶联药物(ADC)SIM0505已获得中国国家药品监督管理局签发的药物临床试验批准通知书,拟开展晚期实体瘤的临床试验。于去年12月28日,SIM0505新药临床试验申请(IND)已获美国食品药品监督管理局(FDA)批准。公司指,SIM0505结合了抗体分子的肿瘤特异靶向性和毒素分子的高杀伤性优势,与传统的化疗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10